Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia.

Leanza, L; Trentin, L; Becker, K A; Frezzato, F; Zoratti, M; Semenzato, G; Gulbins, E; Szabo, I

Leanza, L; Trentin, L; Becker, K A; Frezzato, F; Zoratti, M; Semenzato, G; Gulbins, E; Szabo, I.

Leukemia ; 27(8): 1782-5, 2013 Aug.

Article in En | MEDLINE | ID: mdl-23426166

Subject(s)

Clofazimine/therapeutic use; Ficusin/therapeutic use; Kv1.3 Potassium Channel/antagonists & inhibitors; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Potassium Channel Blockers/therapeutic use; Clofazimine/pharmacology; Ficusin/pharmacology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism; Pancreatitis-Associated Proteins; Potassium Channel Blockers/pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Clofazimine / Potassium Channel Blockers / Kv1.3 Potassium Channel / Ficusin Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2013 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google